Modus Therapeutics Gains Regulatory Approval for Phase 2 Study
Today, Karolinska Development AB announces that its portfolio company, Modus Therapeutics, has successfully received regulatory clearance to commence the second phase of its clinical study targeting chronic kidney disease accompanied by anemia. This important milestone aligns with the company's expected timeline for development of sevuparin, a promising therapeutic candidate.
Overview of the Clinical Study
The second part of the phase 2 clinical study is set to launch in the fourth quarter of the year, reflecting the determination of Modus Therapeutics to address significant health issues faced by patients with chronic kidney conditions. With approval granted by regulatory authorities in Italy, the study aims to assess three different doses of sevuparin, building on the positive data gathered from the initial phase where the treatment was reported to be well-tolerated by participants.
Importance of Sevuparin in Treating Chronic Kidney Disease
Sevuparin is an innovative treatment under investigation for its potential benefits in alleviating symptoms of anemia linked to chronic kidney disease. By focusing on this area, Modus Therapeutics not only hopes to provide relief to patients but also aims to enhance their overall quality of life. The anticipated results from this study could potentially pave the way for new standards of care in managing anemia in chronic kidney disease.
CEO's Insights on Progress
Viktor Drvota, the CEO of Karolinska Development, expressed his enthusiasm regarding this regulatory approval, stating that it is a significant achievement which ensures that Modus Therapeutics can adhere to its projected timeline for sevuparin's clinical development. He emphasized the importance of closely monitoring the study's progress and eagerly awaits the clinical outcomes that could emerge from this endeavor.
Karolinska Development's Commitment to Innovation
Karolinska Development AB plays a pivotal role in nurturing companies that focus on breakthrough medical innovations in the Nordic region. With a commitment to transforming scientific research into viable medical solutions, the firm invests in companies that hold the potential to change the landscape of healthcare. This includes supporting Modus Therapeutics as it navigates the complexities of drug development.
Ownership Structure and Future Plans
Karolinska Development holds a direct ownership stake of 54 percent in Modus Therapeutics and an additional 1 percent via KDev Investments. This strong support reflects the company’s dedication to seeing its portfolio companies thrive and succeed.
Contact Information for Further Inquiries
For those seeking more details regarding the recent developments, Karolinska Development has made contact information available. Viktor Drvota, CEO, is reachable via phone at +46 73 982 52 02 or through email at viktor.drvota@karolinskadevelopment.com. Additionally, Johan Dighed, General Counsel and Deputy CEO, can be contacted at +46 70 207 48 26 or through his email at johan.dighed@karolinskadevelopment.com.
Frequently Asked Questions
What is the focus of Modus Therapeutics' clinical study?
The clinical study focuses on assessing the effectiveness of sevuparin for treating chronic kidney disease related anemia.
When is the second phase of the study expected to begin?
The second phase of the study is set to initiate in the fourth quarter of this year.
What was the outcome of the initial part of the study?
The initial part of the study indicated that sevuparin was well-tolerated by patients.
Who holds the majority ownership in Modus Therapeutics?
Karolinska Development holds a 54 percent direct ownership in Modus Therapeutics.
How can I contact Karolinska Development for more information?
You can reach Viktor Drvota at +46 73 982 52 02 or email viktor.drvota@karolinskadevelopment.com for inquiries.
